Report an error

Spotted something inaccurate in “Noncovalent BTK Inhibitor Pirtobrutinib Shows Promise Beyond Relapsed CLL”? Tell us what’s wrong and we’ll check it against the original source.

Cancel

This form is for factual corrections. We read every report but cannot reply individually.